Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide for freezing of gait in fluctuating Parkinson's disease
2018-004892-11Phase 3Terminated
- Sponsor
- Azienda Ospedaliera di Perugia
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Safinamide add-on with Placebo add-on (2 arms). Primary endpoint: Change from baseline in FOG-scale. Started Oct 2020; status: terminated.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-004892-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004892-11.